NCT02798861 is a clinical trial of Fibroscan 402/530 in Liver Transplant, sponsored by Andres Duarte-Rojo.

Who is sponsoring NCT02798861?

NCT02798861 is sponsored by Andres Duarte-Rojo.

What drugs are being tested in NCT02798861?

Interventions in NCT02798861: Fibroscan 402/530.

What condition does NCT02798861 study?

NCT02798861 studies Liver Transplant, Liver Steatosis, Liver Disease, Primary Non-function, Early Allograft Dysfunction.

Is NCT02798861 still recruiting?

NCT02798861 is currently completed. Last updated 31 July 2020.

Are results published for NCT02798861?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-07-31 · How we verify

NCT02798861

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Controlled Attenuation Parameter (CAP) in Liver Allografts

Completed Results posted Last updated 31 July 2020

What this trial tests

trial testing Fibroscan 402/530 in Liver Transplant in 160 participants. Completed in 1 June 2019.

Timeline

7 September 2016

Primary endpoint
1 June 2019

1 June 2019

Quick facts

Lead sponsor	Andres Duarte-Rojo
Status	Completed
Study type	OBSERVATIONAL
Enrollment	160
Start date	7 September 2016
Primary completion	1 June 2019
Estimated completion	1 June 2019
Sites	3 locations across United States

Drugs / interventions tested

Fibroscan 402/530

Conditions studied

Liver Transplant — all drugs for Liver Transplant →
Liver Steatosis — all drugs for Liver Steatosis →
Liver Disease — all drugs for Liver Disease →
Primary Non-function — all drugs for Primary Non-function →

Sponsor

Andres Duarte-Rojo

Who can join

Adults 18 to 80, any sex, with Liver Transplant or Liver Steatosis. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Controlled Attenuation Parameter (CAP) - Accuracy Primary · Baseline (pre-procurement) to 6 months post liver transplant

CAP accuracy in quantification of liver steatosis to be determined using liver biopsies as reference

Group	Value	95% CI
CAP Assessment	220	176 – 262

LSM Secondary · Pretransplant to 6 months posttransplant

Liver stiffness measurement

Group	Value	95% CI
CAP Assessment	6	4.7 – 8.7

Sponsor's own description

The primary aim is to determine the accuracy of CAP in the quantification of liver steatosis using liver biopsies as reference. Secondarily, investigators will correlate transient elastography (TE) and CAP results, analyze possible associations between CAP/TE and post-liver transplant (LT) clinical outcomes, and evaluate the change in CAP after LT. The study aims to include as many donors as needed to achieve at least 120 transplanted liver allografts.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Liver Transplant

Currently open trials in the same condition.

NCT06254248 — Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT06832189 — EVR and EPO for Liver Transplant Tolerance · Phase 1 · recruiting
NCT07216508 — Liver Transplant CGM · recruiting
NCT07086989 — Cardiovascular Risk in Children With Chronic Conditions Study · recruiting
NCT06813508 — Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH · recruiting

Other Andres Duarte-Rojo trials

Trials by the same sponsor.

NCT04543825 — Usefulness of Cardiopulmonary Exercise Testing for Cardiovascular Risk Estimation and Frailty Assessment in Liver Transp · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02798861 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Andres Duarte-Rojo
Last refreshed: 31 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02798861.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing